Insmed (INSM) Other financing activities (2013 - 2026)
Insmed (INSM) posted quarterly Other financing activities of $30.3 million for Q1 2026, up 2.05% year-over-year from $29.7 million in Q1 2025, and down 12.48% quarter-over-quarter from $34.6 million in Q4 2025.
Analysis
Insmed (INSM) Other financing activities (2013 - 2026) Analysis & Trends
Insmed's Other financing activities history runs 14 years deep, the most recent figure standing at $30.3 million for Q1 2026.
- In Q1 2026, Other financing activities rose 2.05% year-over-year to $30.3 million; the TTM figure through Mar 2026 stood at $136.3 million (down 1.85% YoY), while the FY2025 annual figure was $135.7 million, up 19.85% from the prior year.
- Other financing activities for Q1 2026 stood at $30.3 million, down from $34.6 million in the prior quarter.
- The five-year high for Other financing activities was $68.6 million in Q2 2024, with the low at $1.1 million in Q1 2023.
- The 5-year median for Other financing activities is $7.6 million (2023), against an average of $18.7 million.
- The sharpest annual moves came in 2023 and 2024: Other financing activities tumbled 83.29% in 2023, then surged 1048.23% in 2024.
- Insmed's Other financing activities stood at $2.2 million in 2022, then soared by 251.73% to $7.6 million in 2023, then soared by 79.94% to $13.7 million in 2024, then soared by 152.07% to $34.6 million in 2025, then slipped by 12.48% to $30.3 million in 2026.
- Business Quant data shows INSM's Other financing activities at $30.3 million in Q1 2026, $34.6 million in Q4 2025, and $34.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 28.01 Mn |
| Mar 31, 2026 | 30.31 Mn |
| Dec 31, 2025 | 34.64 Mn |
| Sep 30, 2025 | 34.41 Mn |
| Jun 30, 2025 | 36.97 Mn |
| Mar 31, 2025 | 29.70 Mn |
| Dec 31, 2024 | 13.74 Mn |
| Sep 30, 2024 | 26.88 Mn |
| Jun 30, 2024 | 68.57 Mn |
| Mar 31, 2024 | 4.05 Mn |
| Dec 31, 2023 | 7.64 Mn |
| Sep 30, 2023 | 2.34 Mn |
| Jun 30, 2023 | 7.28 Mn |
| Mar 31, 2023 | 1.14 Mn |
| Dec 31, 2022 | 2.17 Mn |
| Sep 30, 2022 | 4.07 Mn |
| Jun 30, 2022 | 6.45 Mn |
| Mar 31, 2022 | 6.82 Mn |
| Dec 31, 2021 | 6.02 Mn |
| Sep 30, 2021 | 2.49 Mn |